Adocia Secures 6 Million Euros from Vester Finance to Fund Its Platforms
Biopharmaceutical company Adocia has announced the signing of a current account advance agreement with Vester Finance, for a total amount of 6 million euros over 24 months. This operation allows the company to extend its cash horizon until the beginning of the second quarter of 2027.
Details of the Financial Agreement
According to the agreement signed on April 21, 2026, Vester Finance commits to providing Adocia with current account advances up to 6 million euros over a period of 24 months. An initial advance of 1.5 million euros was paid upon signing. The company may request additional advances of up to 1 million euros each. The advances carry an interest rate of 7.0% per annum, payable at maturity in case of cash repayment. They can be repaid in cash or by subscribing to new shares, at any time. Beyond the initial advance, Adocia can suspend or terminate this agreement without cost.
Utilization of the Raised Funds
The raised funds will primarily be used for the development of the BioChaperone® and AdoXLong™ technology platforms, as well as funding the company's operational needs. Adocia has a cash position of 12 million euros as of March 31, 2026. With the 1.5 million euros received upon signing and the full use of the financing, the cash horizon extends to the beginning of the second quarter of 2027, not accounting for future partnership revenues. If all 1.5 million new shares that can be subscribed under this agreement are issued, these shares would represent a maximum of 7.6% of the company's capital stock. Before the transaction, Vester Finance holds 4.2% of the capital and 3.9% of the voting rights. After the transaction, its stake would increase to 11% of the capital and 10.3% of the voting rights.
